NASDAQ: TELOTelomir Pharmaceuticals Inc Stock
$6.87+0.07 (+1.03%)
Updated Apr 26, 2024
TELO Price
$6.87
Fair Value Price
N/A
Market Cap
$203.27M
52 Week Low
$4.76
52 Week High
$20.72
P/E
-14.3x
P/B
59.12x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$13.07M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.39
Operating Cash Flow
-$4M
Beta
-1.08
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
TELO Overview
Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. It develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy recovery by interrupting and preventing the interleukin-17 induced inflammatory pathways. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. on October 10, 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how TELO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
TELO is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
TELO is poor value based on its book value relative to its share price (59.12x), compared to the US Biotechnology industry average (5.85x)
P/B vs Industry Valuation
TELO is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more TELO due diligence checks available for Premium users.
Be the first to know about important TELO news, forecast changes, insider trades & much more!
TELO News
Valuation
TELO price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-14.3x
Industry
14.88x
Market
41.14x
TELO price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
59.12x
Industry
5.85x
TELO is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
TELO's financial health
Profit margin
Revenue
$0.0
Net Income
-$9.3M
Profit Margin
0%
TELO's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$4.8M
Liabilities
$1.3M
Debt to equity
0.39
TELO's short-term assets ($4.77M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TELO's short-term assets ($4.77M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TELO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.1M
Investing
$0.0
Financing
$1.1M
TELO's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
TELO vs Biotech Stocks
Telomir Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.